31 Is deep brain stimulation a treatment option for anorexia nervosa? 23. Agras WS, Robinson AH. Forty years of progress in the treatment of the eating disorders. Nord J Psychiatry. 2008;62 Suppl 47:19-24. 24. Föcker M, Knoll S, Hebebrand J. Anorexia nervosa. European child & adolescent psychiatry. 2013;22 Suppl 1:S29-35. 25. Bulik CM, Berkman ND, Brownley KA, Sedway JA, Lohr KN. Anorexia nervosa treatment: a systematic review of randomized controlled trials. The International journal of eating disorders. 2007;40(4):310-20. 26. Kaye WH, Nagata T, Weltzin TE, Hsu LK, Sokol MS, McConaha C, et al. Double-blind placebo-controlled administration of fluoxetine in restricting- and restrictingpurging-type anorexia nervosa. Biological psychiatry. 2001;49(7):644-52. 27. Mitchell JE, de Zwaan M, Roerig JL. Drug therapy for patients with eating disorders. Curr Drug Targets CNS Neurol Disord. 2003;2(1):17-29. 28. Halmi KA, Eckert E, LaDu TJ, Cohen J. Anorexia nervosa. Treatment efficacy of cyproheptadine and amitriptyline. Arch Gen Psychiatry. 1986;43(2):177-81. 29. Biederman J, Herzog DB, Rivinus TM, Harper GP, Ferber RA, Rosenbaum JF, et al. Amitriptyline in the treatment of anorexia nervosa: a double-blind, placebocontrolled study. J Clin Psychopharmacol. 1985;5(1):10-6. 30. McKnight RF, Park RJ. Atypical antipsychotics and anorexia nervosa: a review. European eating disorders review : the journal of the Eating Disorders Association. 2010;18(1):10-21. 31. Bissada H, Tasca GA, Barber AM, Bradwejn J. Olanzapine in the treatment of low body weight and obsessive thinking in women with anorexia nervosa: a randomized, double-blind, placebocontrolled trial. The American journal of psychiatry. 2008;165(10):1281-8. 32. Brambilla F, Garcia CS, Fassino S, Daga GA, Favaro A, Santonastaso P, et al. Olanzapine therapy in anorexia nervosa: psychobiological effects. Int Clin Psychopharmacol. 2007;22(4):197-204. 33. Attia E, Kaplan AS, Walsh BT, Gershkovich M, Yilmaz Z, Musante D, Wang Y. Olanzapine versus placebo for out-patients with anorexia nervosa. Psychological medicine. 2011;41(10):2177-82. 34. Kafantaris V, Leigh E, Hertz S, Berest A, Schebendach J, Sterling WM, et al. A placebo-controlled pilot study of adjunctive olanzapine for adolescents with anorexia nervosa. J Child Adolesc Psychopharmacol. 2011;21(3):207-12. 35. Brewerton TD. Antipsychotic agents in the treatment of anorexia nervosa: neuropsychopharmacologic rationale and evidence from controlled trials. Current psychiatry reports. 2012;14(4):398-405. 36. Wilson GT, Shafran R. Eating disorders guidelines from NICE. Lancet (London, England). 2005;365(9453):79-81. 37. Beumont P, Hay P, Beumont D, Birmingham L, Derham H, Jordan A, et al. Australian and New Zealand clinical practice guidelines for the treatment of anorexia nervosa. The Australian and New Zealand journal of psychiatry. 2004;38(9):659-70. 38. Couturier J, Lock J. What is recovery in adolescent anorexia nervosa? The International journal of eating disorders. 2006;39(7):550-5. 39. Strober M, Freeman R, Morrell W. The longterm course of severe anorexia nervosa in adolescents: survival analysis of recovery, relapse, and outcome predictors over 10-15 years in a prospective study. The International journal of eating disorders. 1997;22(4):339-60. 40. Herzog DB, Dorer DJ, Keel PK, Selwyn SE, Ekeblad ER, Flores AT, et al. Recovery and relapse in anorexia and bulimia nervosa: a 7.5-year follow-up study. J Am Acad Child Adolesc Psychiatry. 1999;38(7):82937. 41. Kaye WH, Fudge JL, Paulus M. New insights into symptoms and neurocircuit function of anorexia nervosa. Nature reviews Neuroscience. 2009;10(8):573-84. 42. Bulik CM, Slof-Op’t Landt MC, van Furth EF, Sullivan PF. The genetics of anorexia nervosa. Annu Rev Nutr. 2007;27:263-75.
RkJQdWJsaXNoZXIy MjY0ODMw